Please note: The information displayed on this page might be outdated.
Vaccinex, Inc.: Vaccinex is a privately-held, clinical-stage biotechnology company. Its lead product, pepinemab, is an antibody against semaphorin 4D, a novel immunotherapy target to modulate immune response to solid tumors and chronic inflammation that drives neurodegenerative diseases. Vaccinex has an ongoing Phase 2 trial in non-small cell lung cancer (NSCLC) of pepinemab in combination with Merck KGaA’s avelumab, an immune checkpoint inhibitor, and an advanced Phase 2 trial of single agent pepinemab in Huntington’s Disease.
Based in...
US - Middle Atlantic
Public, USA
Market Cap
1895 Mt. Hope Avenue
Rochester, NY 14620
United States

Company Participants at Solebury Trout Corporate Access Calls - May 11&12

  • Maurice Zauderer, Ph.D., President & CEO

Top 10 Holders of Vaccinex, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Point72 Asset Management LP 9.59 1,425,000 2.55 Stakes 7/15/20
MSD Partners LP 6.21 922,546 1.65 13F 6/30/20
The Vanguard Group, Inc. 0.96 142,297 0.25 Funds 8/31/20
Vanguard Group, Inc. (Subfiler) 0.93 138,297 0.25 13F 6/30/20
Oppenheimer & Co., Inc. 0.24 35,351 0.06 13F 6/30/20
Millennium Management LLC 0.21 30,792 0.06 13F 6/30/20
The Bank of New York Co., Inc. 0.11 15,902 0.03 13F 6/30/20
Northern Trust Corp. 0.07 10,728 0.02 13F 6/30/20
BlackRock Fund Advisors 0.07 10,722 0.02 13F 6/30/20
Creative Planning LLC 0.07 10,000 0.02 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.